Fully human antibody VHdomains to generate mono and bispecific CAR to target solid tumors
Abstract
Chimeric antigen receptor (CAR) T cells are effective in B-cell malignancies. However, heterogeneous antigen expression and antigen loss remain important limitations of targeted immunotherapy in solid tumors. Therefore, targeting multiple tumor-associated antigens simultaneously is expected to improve the outcome of CAR-T cell therapies. Due to the instability of single-chain variable fragments, it remains challenging to develop the simultaneous targeting of multiple antigens using traditional single-chain fragment variable (scFv)-based CARs.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 01, 2021
- Source ID
- 10.1136/jitc-2020-002173
Entities
People
- Brian Mcguinness
- Colette Johnston
- Elena Dukhovlinova
- Gianpietro Dotti
- Giovanni Fucà
- Guanmeng Wang
- Hongwei Du
- Hongxia Li
- Peishun Shou
- Xin Zhou
Organizations
- National Cancer Institute
- United States Department of Defense